All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2024-05-24.
From the record
Recursion Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events: an auditor change (8-K item 4.01, 2 times, the latest 2024-05-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+78.3% a year over 7 filed years; profitable in 0 of 7.
From the record
Recursion Pharmaceuticals, Inc.'s 7 filed years say what it did: revenue went from $2 million in fiscal 2019 to $75 million in fiscal 2025, up 78.3% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Recursion Pharmaceuticals, Inc.'s shareholder treatment is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 35% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -57%: lost 57¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Recursion Pharmaceuticals, Inc. lost about 57 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count grew 63.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 44% of 102 in its family; net margin -863.4%.
From the record
Recursion Pharmaceuticals, Inc.'s standing among 102 graded names in its industry family: revenue of $75 million in fiscal 2025 ranks in the top 34% by size; a net margin of -863.4% ranks in the bottom 35%; revenue growth of 23.3% a year over the last 3 filed years ranks in the top 31% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 9% of 110 in its family for leadership; chief executive since 2026.
From the record
Recursion Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Khan, Najat (CEO and President, as filed), filing under that title since 2026-02-10, 9 months (bottom 10% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 2.3 years (bottom 5%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 13%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 46% of 92 in its family for room to expand.
From the record
Recursion Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $754 million against debt of $10 million leaves 50.5% of its assets as net cash, top 31% of its family; cash from operations less capital spending is -506.5% of revenue (bottom 34%); a gross margin of 5% (bottom 14%); research spending of 636.4% of revenue (top 32%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 48% of 100 in its family for growth drivers.
From the record
Recursion Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 23.3% a year over the last three filed years against 78.3% over all 7, slowing (bottom 16% of its family); the newest year grew 26.9% (top 41%); research spending grew 45.1% a year (top 2%); capital spending grew -44.1% a year (bottom 36%) (its annual reports). Recursion Pharmaceuticals, Inc. reported 2 product lines in fiscal 2025: License and Service at $74 million (99%), Grant at $425 thousand (1%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 29% of 72 in its family for expectations against reality.
From the record
Recursion Pharmaceuticals, Inc.'s newest year against its own record: revenue of $75 million in fiscal 2025 came in 4.5% above the $71 million its prior three years' pace pointed to (top 49% of its family); net income of $645 million against a prior three-year average of $344 million (bottom 13%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 23%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made